Please use this identifier to cite or link to this item:
Title: Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Issue Date: 21-Dec-2017
Citation: BMC Gastroenterol.2017 Dec;(17)1:168
Abstract: Hepatitis B virus (HBV) chronic infection affects up to 240 million people in the world and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC). HBV covalently closed circular DNA (cccDNA) plays an essential role in HBV persistence and replication. Current pharmacological treatment with nucleos(t)ide analogues (NA) may suppress HBV replication with little or no impact on cccDNA, hence lifelong treatment is required in the vast majority of patients. Clearances of intrahepatic cccDNA and/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV. Recent promising developments targeting different molecular HBV life cycle steps are being pre-clinically tested or have moved forward in early clinical trials.
PMID: 29268704
Rights: openAccess
Appears in Collections:Hospitales > H. U. Fundación Alcorcón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5740721.pdf800.89 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.